Answers are grounded in this paper and cite their sources.
Chronic viral hepatitis is a worldwide health problem. Complications associated with chronic viral hepatitis include liver failure, cirrhosis and hepatocellular carcinoma. The disease often is asymptomatic, but malaise, weakness and fatigue can occur. Alfa-inter-feron (α-IFN) is the only treatment with proven benefit in chronic viral hepatitis. Common adverse physical and psychiatric effects of therapy are described. The efficacy, however, varies widely. In chronic hepatitis B, α-IFN improves liver aminotransferases and histology, and leads to loss of viral replication in 25–40% of patients. Nucleoside analogues are being evaluated as an alternative treatment. In chronic hepatitis C, α-IFN leads to improvement in liver aminotransferases and histology, and clearance of HCV RNA in 10–25% of patients. The new treatment under investigation is a combination of α-IFN and ribavirin. In chronic hepatitis D, prolonged treatment using similar dosing regimens of α-IFN in chronic hepatitis B result in clearance of HDV RNA in 50% of patients. Relapses are common after treatment discontinuation. Future treatment approaches for chronic viral hepatitis will most likely utilize combination therapies.
No takes yet. Share an insight, caveat, or question.
Nancy P. Lam (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: